SCHEMBL4992848

SCHEMBL4992848

CCC(CCCC1CCCCC1)C(N)CC(=O)O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.40
CYP1A2 P05177 1/20 0.40
METAP1 P53582 1/20 0.39
METAP2 P50579 2/20 0.38
ALDH1A1 P00352 1/20 0.36
KDM5A P29375 3/20 0.36
PHF8 Q9UPP1 3/20 0.36
KDM2A Q9Y2K7 3/20 0.36
KDM4C Q9H3R0 2/20 0.36
KDM4A O75164 1/20 0.36
BMP1 P13497 5/20 0.35
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
MMP2 P08253 1/20 0.34
SIGMAR1 Q99720 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4989077 0.99 MAPT (0.41) MAPTCYP1A2METAP1METAP2ALDH1A1
SCHEMBL4990150 0.96 MAPT (0.41) MAPTCYP1A2METAP1METAP2ALDH1A1
SCHEMBL4984053 0.93 MAPT (0.47) MAPTKDM5APHF8KDM2AKDM4C
SCHEMBL4986911 0.91 METAP1 (0.44) MAPTCYP1A2METAP1METAP2ALDH1A1
SCHEMBL4993143 0.90 METAP1 (0.41) MAPTCYP1A2METAP1METAP2ALDH1A1
SCHEMBL4981822 0.87 METAP1 (0.38) MAPTMETAP1METAP2ALDH1A1
SCHEMBL4986505 0.83 MAPT (0.39) MAPTMETAP1METAP2ALDH1A1
SCHEMBL3999709 0.82 MAPT (0.42) MAPTCYP1A2METAP1METAP2ALDH1A1
SCHEMBL3995552 0.82 MAPT (0.42) MAPTCYP1A2METAP1METAP2ALDH1A1
SCHEMBL3994881 0.82 MAPT (0.42) MAPTCYP1A2METAP1METAP2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1886363-A Amino acids with affinity for the alpha2delta-protein WARNER LAMBERT CO (US) 2006-12-27 CN claimed
US-20050124668-A1 Amino acids with affinity for the alpha2delta-protein WARNER-LAMBERT COMPANY LLC 2005-06-09 US claimed
US-7388023-B2 Amino acids with affinity for the α2δ-protein WARNER-LAMBERT COMPANY LLC (US) 2008-06-17 US disclosed
US-20070129550-A1 AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN WANER-LAMBERT COMPANY LLC (US) 2007-06-07 US disclosed
US-7179934-B2 Amino acids with affinity for the α2δ-protein WARNER-LAMBERT COMPANY LLC (US) 2007-02-20 US disclosed
CN-1886363-A Amino acids with affinity for the alpha2delta-protein WARNER LAMBERT CO (US) 2006-12-27 CN disclosed
EP-1667957-A2 AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN Warner-Lambert Company LLC (US) 2006-06-14 EP disclosed
US-20050124668-A1 Amino acids with affinity for the alpha2delta-protein WARNER-LAMBERT COMPANY LLC 2005-06-09 US disclosed
US-20050101643-A1 Amino acids with affinity for the alpha2delta-protein WARNER-LAMBERT COMPANY LLC 2005-05-12 US disclosed
WO-2005030700-A2 AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA-PROTEIN WARNER-LAMBERT COMPANY LLC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124668-A1 Amino acids with affinity for the alpha2delta-protein SCN2A, SCN1A, OPRD1 MAPT 908/4885CYP1A2 1487/4885METAP1 1825/4885
US-20070129550-A1 AMINO ACIDS WITH AFFINITY FOR THE ALPHA-2-DELTA-PROTEIN SCN2A, OPRD1, SCN1A MAPT 745/4885CYP1A2 1628/4885METAP1 1443/4885
US-20050101643-A1 Amino acids with affinity for the alpha2delta-protein SCN2A, OPRD1, SCN1A MAPT 1029/4885CYP1A2 1464/4885METAP1 1583/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.